Systems, devices, and methods for reconstitution of therapeutic powders, mixing precursor solutions, and extrusion sealants to control bleeding and seal fluid and air leaks
Through the design of the sealant applicator system, the combination of syringe and vial and the propulsion mechanism of the plunger is used to solve the problem of bleeding and leakage control in surgical operations, and efficient sealing and hemostasis effects are achieved.
Patent Information
- Application Number
- CN202380030738.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-31
- Filing Date
- 2023-03-15
- Publication Date
- 2024-11-12
AI Technical Summary
There are challenges in surgical procedures, especially during minimally invasive surgery, controlling bleeding, sealing wounds, preventing air leakage during lung surgery and fluid leakage during organ resection, and prior art hemostasis and sealants lack sufficient after curing Adhesion and elasticity lead to poor results.
A sealant applicator system was designed to store liquid and powder-like reactive components through a combination of two syringes and two vials, respectively, and the combination of double-barrel plunger and puncture elements ensured that the components were used before use. Keep isolated and mix by pushing the plunger and deliver sealant or hemostatic agent.
Rapid mixing and delivery of sealants or hemostatic agents is achieved, improving adhesion and elasticity to tissues, effectively controlling bleeding and leakage, shortening surgical time and reducing postoperative complications.
Smart Images

Figure CN118946316A_ABST
Abstract
Description
Background Art Technical Field
[0001] The present patent application generally relates to systems, devices and methods for dispensing therapeutic fluids during surgical procedures, and more specifically to systems, devices and methods for dispensing therapeutic fluids for controlling bleeding, sealing wounds, sealing air leaks, sealing fluid leaks and graft fixation during lung surgery.
[0002] Description of Related Technology
[0003] Mammals may suffer from bleeding due to wounds or during surgical procedures in a wide variety of situations. In some cases, the bleeding is relatively minor and will stop due to normal coagulation or by using simple first aid techniques. However, in other cases, heavy bleeding may occur. The latter situation requires the use of specialized equipment and materials, as well as the services of trained personnel, in order to administer effective first aid to control excessive bleeding.
[0004] In order to solve the above more challenging situations, various materials have been developed for controlling excessive bleeding. For example, local absorbable hemostats (TAHs) are widely used in surgical applications. TAHs include products based on oxidized cellulose (OC), oxidized regenerated cellulose (ORC), gelatin, collagen, chitin, chitosan, starch, etc. In order to improve hemostatic properties, scaffolds based on the above materials can be combined with coagulation factors of biological origin (such as thrombin and fibrinogen).
[0005] In surgical procedures, bleeding control is key to minimizing blood loss, shortening surgical duration, and reducing postoperative complications.
[0006] In recent years, minimally invasive surgery (MIS) techniques (e.g., thoracic surgery) have become an alternative to conventional surgical techniques to perform a variety of surgical procedures. MIS surgery differs from conventional surgery in that multiple devices and / or surgical tools can be introduced into the body through cannulas and trocars inserted into small incisions made in the body. Due to the use of MIS techniques, trauma to the body is greatly reduced, which shortens the patient's recovery time.
[0007] One type of minimally invasive surgery involves laparoscopic surgery, which is used to treat hernias, colon disease, gastroesophageal reflux disease, gallbladder disorders, lung disorders, etc. Typically, patients who undergo laparoscopic surgery are able to return home after a short recovery period (within hours after undergoing surgery).
[0008] One challenge that arises when performing MIS surgery involves controlling bleeding at the surgical site.During laparoscopic surgery, the surgeon has significantly less access to the surgical site or cavity than during conventional open surgery.
[0009] In response, tissue sealants and other bioadhesive materials have been developed for closing incisions and wounds at surgical sites. Tissue sealants may include fibrin sealants, which are composed of thrombin and fibrin raw materials, but other preparations are also available. Typically, the individual components of tissue sealants (e.g., thrombin and fibrinogen) are stored in isolated reservoirs, respectively, because once they contact each other, these components will react rapidly. In many cases, these two individual components are mixed together for the first time before being applied to tissue.
[0010] Once mixed, the components coagulate very quickly to produce an adhesive gel within a short period of time (eg, within 10 to 20 seconds).
[0011] There have been some developments related to systems for reconstituting therapeutic powders to form therapeutic solutions and delivering the therapeutic solutions to patients. For example, U.S. Pat. No. 4,723,691 discloses a handheld and manually operated powder dispenser having a container including a handle / nozzle section terminating at its discharge end in an unobstructed powder dispensing opening, a hand grip section, and a central flexible bellows section connected between the handle / nozzle section and the hand grip section. The bellows section is adapted to collapse axially and expand to serve as a pump. The inner diameter of the handle / nozzle section decreases substantially linearly and continuously as a function of the length of the handle / nozzle section in a direction toward the powder dispensing opening.
[0012] US2003 / 0040701 discloses a dual chamber syringe in which a dual function piston divides the syringe into two compartments, containing powder or fluid in one compartment and fluid in the other compartment. To mix the two substances, before or during the retraction of the piston, a passage is opened between the two compartments to force the substances to mix in the front compartment. During the forward movement of the piston, the passage between the two compartments is closed to force the mixture of substances through the discharge opening of the syringe.
[0013] U.S. Patent No. 6,458,095 discloses a dispenser for simultaneously dispensing a first component and a second component of an adhesive tissue sealant, wherein at least the first component is stored in the dispenser as a dry powder that is dissolved by the introduction of a solvent prior to use. The dispenser includes a first container having a first septum at one end, an open end opposite the first septum, and a first removable plug disposed therein. The first container holds a certain amount of the first component stored in dry powder form between the first septum and the first removable plug. The dispenser includes a second container having a second septum at one end, an open end opposite the second septum, and a second removable plug disposed therein, and the second container holds a certain amount of the second component.
[0014] U.S. Patent No. 6,699,229 discloses a fluid transfer and mixing device for aseptic mixing of a powder component with a fluid component. The device includes a first adapter that can be connected to a container containing the powder component and a second adapter that can be removably connected to the first adapter and can also be easily connected to a container containing a fluid such as a diluent to allow the diluent to be aseptically mixed with the powder. In use, a syringe is connected to the first adapter so that a mixture of the powder and the diluent can be aseptically aspirated from the first container for delivery to a patient.
[0015] US2010 / 0219200 discloses a device and method for mixing two components and delivering the mixture to a patient. The device contains a mixing chamber for mixing a liquid component and a powder component. The liquid component and the powder component are mixed in the mixing chamber by the rotation of a foldable mixing element. A plunger is pushed through the mixing chamber to force the mixture out of the mixing chamber and deliver the mixture to the patient.
[0016] US Patent No. 7,923,031 discloses a powder delivery system comprising a chamber for storing a hemostatic composition comprising dry gelatin powder having an average particle size ranging from 30 microns to 250 microns and hyaluronic acid. The system comprises a chamber having at least one discharge opening of a size suitable for dispensing the composition.
[0017] U.S. Patent No. 7,946,417 discloses an apparatus and method for mixing two components and delivering the mixture to a patient. The apparatus contains a mixing chamber for mixing a liquid component and a powder component. The liquid component and the powder component are mixed in the mixing chamber by rotation of a foldable mixing element. A plunger is then pushed through the mixing chamber to force the mixture out of the mixing chamber and deliver the mixture to the patient.
[0018] US2011 / 0178495 discloses a powder supply device, which includes a gas powder mixer providing a gas powder mixing chamber and a powder dispenser (bellows) screwed into the gas powder mixer and connected to the gas powder mixing chamber therein. Hemostatic powder is filled in the powder dispenser (bellows) and is suitable for delivery to a bleeding site via a powder delivery conduit.
[0019] U.S. Patent No. 7,967,779 discloses a mixing syringe having a first sealed chamber containing powder (powder housing) and a second sealed chamber containing liquid (liquid housing). When the user needs to inject the patient, the device remains roughly upright when the plunger is pressed, which causes the piercing element to pierce the foil seal separating the two chambers. The liquid then drops into the powder housing. The liquid flows through a channel in the piston located in the powder housing, where it contacts the powder. When the user continues to press the plunger downward, the piercer stays in the piston and seals the channel through the piston, thereby locking the piercer and the piston together. The device is then ready for injection. When the plunger is further pressed, the piston expels the powder and liquid mixture through the needle.
[0020] U.S. Patent No. 10,183,132 assigned to Ethicon LLC (the disclosure of which is incorporated herein by reference) teaches an integrated delivery device that can be operated with one hand and delivers a liquid medicament and a powder medicament to a tissue or wound from a liquid medicament extrusion subunit and a powder medicament extrusion subunit. Each extrusion subunit has an actuator for the liquid medicament and the powder medicament contained therein positioned proximate to each other at the proximal end of the extrusion subunit and a delivery cannula for each of the extrusion subunits positioned proximate to each other at the distal end of the extrusion subunit.
[0021] U.S. Patent No. 10,507,293 to Goodman et al., assigned to Ethicon, of Somerville, New Jersey, (the disclosure of which is incorporated herein by reference) teaches a device for extruding hemostatic powder. The device has an elongated reservoir having a manual air pump such as a bellows at the proximal end and an extrusion port at the distal end. A porous filter is slidably disposed in the reservoir between the bellows and the plunger and the extrusion port, and a spring is disposed in the reservoir between the air pump and the plunger. Powder is disposed in the reservoir between the porous filter and the extrusion port, and the pump is in fluid communication with the extrusion port through the porous filter and through the powder.
[0022] US2021 / 0101162 assigned to Ethicon discloses a spray device (the disclosure of which is incorporated herein by reference), the spray device comprising a first spray tip having a first fluid passage defining a first flow area and a second spray tip comprising a second fluid passage defining a second flow area, the second flow area being greater than the first flow area of the first spray tip. The first spray tip and the second spray tip are juxtaposed and spaced apart from each other at the distal end of the spray device. When a first fluid having a certain volume flow rate is introduced into the first spray tip and a second fluid having the same certain volume flow rate is introduced into the second spray tip, the first fluid will flow through the first fluid passage at a greater speed than the speed at which the second fluid flows through the second fluid passage.
[0023] Several efforts have been made to control intraoperative and postoperative bleeding, fluid leaks, and air leaks that occur during thoracic surgery, such as during organ resection.
[0024] Resection is a surgical procedure involving the removal of a portion of a tissue or organ. Resections of a variety of organs, including the liver, lungs, and gastrointestinal system, present surgeons with a number of unique problems related to effectively managing postoperative bleeding and fluid and air leaks.
[0025] During organ resection surgery, surgeons manage heavy bleeding at the resection surface by using tourniquets, extensive suturing, etc. Some surgeons use adhesive fluids (e.g., synthetic adhesives, fibrin glue gels), which are limited because they may flow away from the resection surface before fully curing or may easily flake off after curing because they lack sufficient adhesion or appropriate elastic properties to the underlying tissue.
[0026] Liver Resection. A surgical procedure involving the removal of all or part of the liver is commonly referred to as a hepatectomy. Partial hepatectomy is the preferred method for removing solid tumors from the liver. During liver resection, tissue margins within the resected area are destroyed, and the internal parenchyma and flow system are exposed. Reconstruction of proper margins does not occur immediately, but requires a prolonged tissue healing process that can last from days to weeks. During the tissue healing process, the resected tissue may bleed and / or leak organ-specific fluids (e.g., bile), which can lead to postoperative complications. One study found that the rate of bile leakage was approximately 5% after liver resection surgery, which significantly increases the likelihood of postoperative complications in patients.
[0027] Lung Resection. Lung resection surgery often requires extensive tissue manipulation and handling, which results in a high incidence of postoperative air leaks. Standardized techniques for addressing air leaks involve suturing or stapling lung tissue. However, due to the inherent friability of lung parenchyma, these techniques are often ineffective in creating an airtight seal, especially in patients with emphysema. In some cases, topical adhesives are applied directly to the pleural abrasions or to the staple lines, however, these techniques are often insufficient to prevent air leaks.
[0028] GI Resection. Gastrointestinal (GI) surgery typically involves the removal of a large portion of a patient's intestinal anatomy in order to effectively treat the disease. After the GI tissue is removed, a surgeon is required to reconstruct the patient's digestive system. GI reconstruction is complicated by the delicate structure of the intestine, the limited blood supply to the lower colon, the surgeon's limited access to the complex anatomy, and the pathology that often affects the surrounding tissue. However, even if the surgeon operates very carefully during GI reconstruction surgery, a certain percentage of patients will still experience complications due to leaks at the anastomotic sites created by the surgery. GI leaks can have catastrophic consequences, requiring additional surgeries and treatments that are often unsuccessful in dealing with the leak.
[0029] In view of the above, many efforts have been made to effectively handle intraoperative and postoperative bleeding and fluid and air leakage. For example, when excising solid organs, surgeons usually handle heavy bleeding at the excision surface by using tourniquets and a large number of sutures. A small amount of bleeding and fluid leakage are usually handled by using an adhesive fluid (e.g., synthetic adhesive, fibrin glue) to cover the excision surface, but the limited success achieved by these methods, because the adhesive fluid tends to flow away from the excision surface before solidification and / or peel off after solidification, because the solidified adhesive lacks sufficient adhesion or suitable elastic properties to the underlying tissue.
[0030] Sold by Covidien Hemostatic patches are used to seal the surface of excised tissue. The hemostatic patch consists of an oxidized regenerated cellulose (ORC) layer and a reactive polyethylene glycol (PEG) layer. The patch is applied to the tissue surface by applying pressure on the surface. The stroma is opaque, so the surgeon cannot see through it when applying pressure to the resection surface. Hemostatic patches are used to assess the condition of the resected surface. The patches are also rigid, have low flexibility, and therefore may not achieve good tissue conformity or maintain compliance with tissue movement.
[0031] Despite the above advances, there remains a need for improved systems, devices and methods to enable surgeons to effectively seal organ and tissue surfaces and prevent and / or successfully manage bleeding, fluid leakage and / or air leakage from organ and tissue surfaces (e.g., resection surfaces) during and after surgery. Summary of the invention
[0032] In one embodiment, a sealant applicator system for mixing and delivering a sealant or hemostatic agent during surgery preferably includes two syringes for mixing and reconstituting powdered reactive components. In one embodiment, the two syringes are preferably held side by side by a syringe holder.
[0033] In one embodiment, a syringe holder may be formed by connecting two syringe holder components, each syringe holder component having two hollow cavities configured to accommodate at least a portion of two syringes.
[0034] In one embodiment, each syringe contains a liquid (eg, diluent; buffer solution; catalyst; initiator; activation fluid, etc.) that can be mixed with the powdered reactive components to reconstitute the powdered reactive components.
[0035] In one embodiment, the sealant applicator system preferably includes two vials, each vial is configured to hold a powdered reactive component. In one embodiment, each vial is closed by a pierceable sealing membrane (e.g., septum; stopper) that seals the vial opening to maintain the powdered reactive component in a dry state during transportation and storage.
[0036] In one embodiment, two vials are held side by side in a vial holder. In one embodiment, the vial holder comprises two piercing elements, each piercing element having a proximal end with a central opening or hub and a distal end with a spike, each spike having a pointed tip that can pierce one of the sealing membranes. In one embodiment, the piercing elements are held side by side in the vial holder, with the pointed tips of the spikes pointing toward the sealing membrane.
[0037] In one embodiment, a vial holder may be formed by connecting two vial holder components, each vial holder component having two hollow cavities configured to accommodate a vial and at least a portion of a piercing element.
[0038] In one embodiment, the side-by-side piercing elements are slidably movable in the vial holder, wherein the tips of the spikes are configured to pierce the sealing membrane when moved towards the sealing membrane.
[0039] In one embodiment, the proximal end of each puncture element preferably includes a port that can be connected to the distal end of one of the syringes. Each puncture element preferably has an elongated conduit extending along the length of the puncture element between the port at the proximal end of the puncture element and the tip at the distal end.
[0040] In one embodiment, the piercing element has a proximal end coupled to the distal end of the syringe for establishing fluid communication between the syringe and a corresponding vial.
[0041] In one embodiment, the sealant applicator system may include an elongated extrusion tip having a mixing tip at a distal end and a housing at a proximal end adapted to be connected to the syringe.
[0042] In one embodiment, the elongated extrusion tip may include a cannula with two lumens for delivering the two components of the sealant from the syringe to the mixing tip.
[0043] In one embodiment, the elongated extruded tip is bendable at the distal end. In one embodiment, the bendable portion of the elongated extruded tip may include a malleable component having shape memory properties for maintaining the orientation of the mixing tip after the distal end of the elongated extruded tip has been bent into a particular shape.
[0044] In one embodiment, the sealant applicator system may include a single-piece syringe housing having a side-by-side dual barrel chamber for holding liquids for reconstitution and mixing.
[0045] In one embodiment, the sealant delivery system preferably includes a syringe assembly including a first syringe and a second syringe side-by-side, the first syringe having a first fluid chamber and the second syringe having a second fluid chamber.
[0046] In one embodiment, the sealant delivery system preferably includes a vial assembly coupled to a distal end of a syringe assembly, the vial assembly including a first vial and a second vial in a side-by-side arrangement.
[0047] In one embodiment, the vial assembly and the syringe assembly preferably have structural features that ensure that the first syringe can only be coupled to the first vial, and the second syringe can only be coupled to the second vial. Therefore, the design of the vial assembly and the syringe assembly is expected to ensure that the first syringe always matches the first vial, and the second syringe always matches the second vial. In one embodiment, if a medical professional attempts to couple the first syringe to the second vial and the second syringe to the first vial, the structural features of the syringe assembly and the vial assembly will prevent the distal end of the syringe assembly from connecting to the proximal end of the vial assembly.
[0048] In one embodiment, the first vial has a proximal end that aligns with the distal end of the first syringe.
[0049] In one embodiment, the first vial comprises a first vial opening closed at a proximal end thereof by a first sealing membrane.
[0050] In one embodiment, the second vial has a proximal end that aligns with the distal end of the second syringe.
[0051] In one embodiment, the second vial comprises a second vial opening closed at a proximal end thereof by a second sealing membrane.
[0052] In one embodiment, the vial assembly preferably includes a first piercing element located between the distal end of the first syringe and the proximal end of the first vial. The first piercing element may have a first piercing spike protruding from a distal end thereof.
[0053] In one embodiment, the first piercing element is capable of moving between a retracted position and an extended position, wherein in the retracted position, the first piercing spike is located proximal to the first sealing membrane, and in the extended position, the first piercing spike penetrates the first sealing element for piercing the first sealing membrane, thereby providing fluid communication between the first fluid chamber of the first syringe and the first vial.
[0054] In one embodiment, the vial assembly includes a second piercing element located between the distal end of the second syringe and the proximal end of the second vial. The second piercing element may have a second piercing spike protruding from its distal end.
[0055] In one embodiment, the second piercing element is capable of moving between a retracted position and an extended position, wherein in the retracted position, the second piercing spike is located proximal to the second sealing membrane, and in the extended position, the second piercing spike passes through the second sealing element for piercing the second sealing membrane, thereby providing fluid communication between the second fluid chamber of the second syringe and the second vial.
[0056] In one embodiment, the first piercing element defines a first fluid passage extending along its length for providing a first fluid communication between the first fluid chamber of the first syringe and the first vial.
[0057] In one embodiment, the second piercing element defines a second fluid passage extending along its length for providing a second fluid communication between the second fluid chamber of the second syringe and the second vial.
[0058] In one embodiment, the first fluid pathway and the second fluid pathway are isolated from each other.
[0059] In one embodiment, a first liquid can be disposed within a first fluid chamber of a first syringe and a first powdered reactive component can be disposed within a first vial. In one embodiment, the first liquid and the first powdered reactive component are configured to be mixed together to reconstitute the first powdered reactive component to form a first solution (e.g., a first precursor; a first therapeutic solution, etc.).
[0060] In one embodiment, a second liquid can be disposed within the second fluid chamber of the second syringe and a second powdered reactive component can be disposed within the second vial. In one embodiment, the second liquid and the second powdered reactive component are configured to be mixed together to reconstitute the second powdered reactive component to form a second solution (e.g., a second precursor; a second therapeutic solution, etc.).
[0061] In one embodiment, the vial assembly housing may include a first guide channel (e.g., a cavity) extending between a proximal end and a distal end of the vial assembly housing. In one embodiment, a first piercing element is disposed in the first guide channel and is configured to move (e.g., slide) between a retracted position and an extended position.
[0062] In one embodiment, the vial assembly housing may include a second guide channel (e.g., a cavity) extending between the proximal end and the distal end of the vial assembly housing. In one embodiment, the second piercing element is disposed in the second guide channel and is configured to move (e.g., slide) between a retracted position and an extended position.
[0063] In one embodiment, the vial assembly housing may include a first proximal protrusion extending into the first guide channel and a first distal protrusion extending into the first guide channel, the first proximal protrusion being adapted to contact the first puncture element to hold the first puncture element in a retracted position, the first distal protrusion being adapted to contact the first puncture element to hold the first puncture element in an extended position. Thus, in one embodiment, the first puncture element can be fixed (e.g., locked) in a retracted position or an extended position.
[0064] In one embodiment, the vial assembly housing may include a second proximal protrusion extending into the second guide channel and a second distal protrusion extending into the first guide channel, the second proximal protrusion being adapted to contact the second puncture element to hold the second puncture element in a retracted position, the second distal protrusion being adapted to contact the first puncture element to hold the first puncture element in an extended position. Thus, in one embodiment, the second puncture element can be fixed (e.g., locked) in a retracted position or an extended position.
[0065] In one embodiment, the first puncture element may include a first resilient flange adapted to sequentially engage a first proximal protrusion and a first distal protrusion of the vial assembly housing when the first puncture element moves from a retracted position to an extended position within the first guide channel. When a force is applied to the proximal end of the first puncture element to slide the first puncture element toward the distal end of the vial housing, the first resilient element may bend to enable the first puncture element to slide from the retracted position to the extended position. In one embodiment, when the first puncture element has moved to the extended position, the first resilient element preferably maintains the first puncture element in the extended position.
[0066] In one embodiment, the second puncture element may include a second resilient flange adapted to sequentially engage a second proximal protrusion and a second distal protrusion of the vial assembly housing when the second puncture element moves from the retracted position to the extended position within the second guide channel. When a force is applied to the proximal end of the second puncture element to slide the second puncture element toward the distal end of the vial housing, the second resilient element may bend to enable the second puncture element to slide from the retracted position to the extended position. In one embodiment, when the second puncture element has moved to the extended position, the second resilient element preferably maintains the second puncture element in the extended position.
[0067] In one embodiment, the first piercing element may have a central opening at its proximal end, and the first syringe may have a first dispensing tip protruding from its distal end that is inserted into the central opening at the proximal end of the first piercing element.
[0068] In one embodiment, the second piercing element may have a central opening at its proximal end, and the second syringe may have a second dispensing tip protruding from its distal end that is inserted into the central opening at the proximal end of the second piercing element.
[0069] In one embodiment, the syringe assembly may include a double barrel plunger including a first plunger rod inserted into the proximal end of a first syringe and a second plunger rod inserted into the proximal end of a second syringe. A tab (e.g., a thumb tab) may interconnect the proximal end of the first plunger rod and the proximal end of the second plunger rod.
[0070] In one embodiment, the double barrel plunger is movable toward the distal end of the syringe assembly for forcing the first liquid into the first vial and forcing the second liquid into the second vial.
[0071] In one embodiment, a vial assembly for a sealant delivery system may include a vial assembly housing having a proximal end and a distal end, the vial assembly housing having first and second side-by-side guide channels extending between the proximal and distal ends of the vial assembly housing.
[0072] In one embodiment, the first vial is secured to the vial assembly housing.In one embodiment, the first vial has a proximal end aligned with the first guide channel and a first vial opening closed at its proximal end by a first sealing membrane.
[0073] In one embodiment, the vial assembly includes a first puncture element disposed in a first guide channel and capable of moving between a retracted position and an extended position, wherein the first puncture element is located proximal to the first sealing membrane, and wherein the first puncture element passes through the first sealing element for puncturing the first sealing membrane.
[0074] In one embodiment, the second vial is secured to the vial assembly housing.In one embodiment, the second vial has a proximal end aligned with the second guide channel and a second vial opening closed at its proximal end by a second sealing membrane.
[0075] In one embodiment, the vial assembly includes a second puncture element disposed in the second guide channel and capable of moving between a retracted position and an extended position, wherein the second puncture element is located proximal to the second sealing membrane, and wherein the second puncture element passes through the second sealing element for puncturing the second sealing membrane.
[0076] In one embodiment, the first puncture element has a proximal end and a distal end. In one embodiment, the first puncture element includes a central opening at its proximal end, the central opening defining a first fluid passage extending along the length of the first puncture element.
[0077] In one embodiment, the first piercing element comprises a first piercing spike protruding from a distal end of the first piercing element.
[0078] In one embodiment, the second puncture element has a proximal end and a distal end. In one embodiment, the second puncture element has a central opening at its proximal end, the central opening defining a second fluid passage extending along the length of the second puncture element.
[0079] In one embodiment, the second piercing element comprises a second piercing spike protruding from a distal end of the second piercing element.
[0080] In one embodiment, the first and second fluid pathways extending through the respective first and second puncture elements are isolated from one another.
[0081] In one embodiment, the vial assembly housing preferably includes a first proximal protrusion extending into the first guide channel and a first distal protrusion extending into the first guide channel, wherein the first proximal protrusion is adapted to contact the first puncture element to maintain the first puncture element in a retracted position, and the first distal protrusion is adapted to contact the first puncture element to maintain the first puncture element in an extended position.
[0082] In one embodiment, the vial assembly housing preferably includes a second proximal protrusion extending into the second guide channel and a second distal protrusion extending into the second guide channel, the second proximal protrusion being adapted to contact the second puncture element to hold the second puncture element in a retracted position, the second distal protrusion being adapted to contact the second puncture element to hold the second puncture element in an extended position.
[0083] In one embodiment, the first piercing element may include a first resilient flange adapted to sequentially engage a first proximal protrusion and a first distal protrusion of the vial assembly housing when the first piercing element moves from a retracted position to an extended position within the first guide channel.
[0084] In one embodiment, the second piercing element may include a second resilient flange adapted to sequentially engage the second proximal protrusion and the second distal protrusion of the vial assembly housing when the second piercing element moves from the retracted position to the extended position within the second guide channel.
[0085] In one embodiment, the sealant delivery system may include a vial assembly.In one embodiment, the sealant delivery system may have a syringe assembly including a first syringe and a second syringe side-by-side, the first syringe having a first fluid chamber and the second syringe having a second fluid chamber.
[0086] In one embodiment, the distal end of the syringe assembly can be connected to the proximal end of the vial assembly housing so that the distal end of the first syringe is aligned with the central opening at the proximal end of the first puncture element and the distal end of the second syringe is aligned with the central opening at the proximal end of the second puncture element.
[0087] In one embodiment, the first syringe has a first dispensing tip protruding from its distal end, which is in fluid communication with the first fluid compartment of the first syringe. In one embodiment, the first dispensing tip is inserted into the central opening at the proximal end of the first piercing element for providing fluid communication between the first fluid chamber and a first fluid passage extending along the length of the first piercing element.
[0088] In one embodiment, the second syringe has a second dispensing tip protruding from its distal end, which is in fluid communication with the second fluid compartment of the second syringe. In one embodiment, the second dispensing tip is inserted into the central opening at the proximal end of the second piercing element for providing fluid communication between the second fluid chamber and a second fluid passage extending along the length of the second piercing element.
[0089] In one embodiment, a first liquid is disposed in a first fluid chamber of a first syringe and a first powdered reactive component is disposed in a first vial of the vial assembly.
[0090] In one embodiment, the first fluid pathway provides fluid communication between the first fluid chamber and the first vial when the first piercing element is moved to the extended position.
[0091] In one embodiment, a second liquid is disposed in a second fluid chamber of a second syringe and a second powdered reactive component is disposed in a second vial of the vial assembly.
[0092] In one embodiment, the second fluid pathway provides fluid communication between the second fluid chamber and the second vial when the second piercing element is moved to the extended position;
[0093] In one embodiment, the sealant delivery system preferably includes a syringe assembly including a first syringe and a second syringe side-by-side, the first syringe having a first fluid chamber containing a first fluid and the second syringe having a second fluid chamber containing a second fluid.
[0094] In one embodiment, a sealant delivery system may include a vial assembly coupled to a distal end of a syringe assembly, the vial assembly including a first vial and a second vial in a side-by-side arrangement.
[0095] In one embodiment, the first vial contains a first powdered reactive component. In one embodiment, the first vial has a proximal end aligned with the distal end of the first syringe and a first vial opening closed at its proximal end by a first sealing membrane.
[0096] In one embodiment, the second vial contains a second powdered reactive component.In one embodiment, the second vial has a proximal end aligned with the distal end of the second syringe and a second vial opening closed at its proximal end by a second sealing membrane.
[0097] In one embodiment, the vial assembly preferably includes a first piercing element located between the distal end of the first syringe and the first sealing film. In one embodiment, the first piercing element is movable between a retracted position and an extended position, in which the first piercing element is located proximal to the first sealing film, and in which the first piercing element pierces the first sealing film to provide fluid communication between the first fluid chamber and the first vial.
[0098] In one embodiment, the vial assembly preferably includes a second piercing element located between the distal end of the second syringe and the second sealing film. In one embodiment, the second piercing element is movable between a retracted position and an extended position, in which the second piercing element is located proximal to the second sealing film, and in which the second piercing element pierces the second sealing film to provide fluid communication between the second fluid chamber and the second vial.
[0099] In one embodiment, the syringe assembly may include a double barrel plunger including a first plunger rod inserted into a proximal end of a first syringe and a second plunger rod inserted into a proximal end of a second syringe.
[0100] In one embodiment, a tab interconnects the proximal end of the first plunger rod and the proximal end of the second plunger rod.
[0101] In one embodiment, the double barrel plunger is movable toward the distal end of the syringe assembly for forcing a first liquid into a first vial for reconstitution of a first powdered reactive component to produce a first solution and forcing a second liquid into a second vial for reconstitution of a second powdered reactive component to produce a second solution.
[0102] The first solution and the second solution can be mixed together to form a sealant or hemostat that can be applied to tissue.
[0103] In one embodiment, the double barrel plunger can be repeatedly reciprocated (e.g., back and forth) in the distal direction and the proximal direction to speed up the solution mixing process (e.g., reconstitute the powdered reactive components). In one embodiment, the double barrel plunger can be repeatedly reciprocated in the proximal direction and the distal direction for about 20, 30, 40 or more cycles. The double barrel plunger preferably reciprocates back and forth until the first liquid has been completely mixed with the first powdered reactive component and the second liquid has been completely mixed with the second powdered reactive component.
[0104] In one embodiment, after the first and second reactive powder components have been reconstituted, the double barrel plunger can be retracted to draw the first solution into the first syringe and the second solution into the second syringe. At this stage, the first and second solutions are preferably kept isolated from each other.
[0105] In one embodiment, the vial assembly housing may include first and second side-by-side guide channels (eg, cavities) extending between proximal and distal ends of the vial assembly housing.
[0106] In one embodiment, the vial assembly housing includes a first proximal protrusion extending into the first guide channel and a first distal protrusion extending into the first guide channel, wherein the first proximal protrusion is adapted to contact the first puncture element to maintain the first puncture element in a retracted position, and the first distal protrusion is adapted to contact the first puncture element to maintain the first puncture element in an extended position.
[0107] In one embodiment, the vial assembly housing includes a second proximal protrusion extending into the second guide channel and a second distal protrusion extending into the second guide channel, the second proximal protrusion being adapted to contact the second puncture element to hold the second puncture element in a retracted position, the second distal protrusion being adapted to contact the second puncture element to hold the second puncture element in an extended position.
[0108] In one embodiment, the powder vial can hold about 0.1 to 2 grams of powder. In one embodiment, the powder vial can hold about 0.4 to 0.5 grams, and more preferably about 0.408 grams of powdered reactive components.
[0109] In one embodiment, the vial may have a size of about 2 ml to 10 ml, more preferably about 3 ml to 5 ml, and even more preferably about 4 ml.
[0110] In one embodiment, the vial may be made of glass or a polymeric material (eg, plastic).
[0111] These and other preferred embodiments of the present patent application will be described in more detail below. BRIEF DESCRIPTION OF THE DRAWINGS
[0112] Figure 1 is a perspective view of components of a sealant delivery system including a syringe assembly, a sealant delivery assembly, and a vial assembly according to one embodiment of the present patent application.
[0113] Figure 2 yes Figure 1 A perspective view of the syringe assembly is shown.
[0114] Figure 3 yes Figure 2 Exploded view of the syringe assembly shown.
[0115] Figure 4A yes Figure 2 A top cross-sectional view of the syringe assembly is shown.
[0116] Figure 4B yes Figure 2 A side cross-sectional view of a syringe assembly is shown.
[0117] Figure 5A yes Figure 2 A perspective view of the vial assembly is shown.
[0118] Figure 5B yes Figure 5A A front elevation view of the vial assembly is shown.
[0119] Figure 6 yes Figure 5A and Figure 5B Exploded view of the vial assembly shown.
[0120] Figure 7 yes Figure 5A and Figure 5B A cross-sectional view of the vial assembly is shown.
[0121] Fig. 8A A schematic diagram of a device according to one embodiment of the present patent application having a first puncture element and a second puncture element in a retracted position is shown. Figure 7 Vial assembly.
[0122] Figure 8B An embodiment of the present patent application is shown. Fig. 8A The vial assembly comprises a first piercing element and a second piercing element in an extended position for piercing a first sealing film and a second sealing film sealing the vial openings of the respective first and second vials.
[0123] Fig. 9 yes Figure 1 A perspective view of the seal delivery assembly is shown.
[0124] Fig.10 yes Fig. 9 An exploded view of the seal delivery assembly is shown.
[0125] Fig.11 yes Fig. 9 A top cross-sectional view of the proximal end of a sealant delivery assembly is shown.
[0126] Fig.12 yes Fig. 9 A cross-sectional view of the distal end of a sealant delivery system including a spray tip is shown.
[0127] Fig.13A Shows Fig. 8A A side view of a vial assembly of the present invention is shown with the first piercing element and the second piercing element in a retracted position.
[0128] Fig. 13B Shows Figure 8B A side view of a vial assembly of FIG. 1 , wherein the first piercing element and the second piercing element are in an extended position.
[0129] Fig.14 Shows Figure 1 A top view of the syringe assembly is shown.
[0130] Fig.15A Stages of a method of coupling a distal end of a syringe assembly with a proximal end of a vial assembly according to one embodiment of the present patent application are shown.
[0131] Fig. 15B The syringe assembly is shown after the distal end of the syringe assembly has been coupled to the proximal end of the vial assembly. Fig.15A Syringe assembly and vial assembly.
[0132] Fig. 15C According to one embodiment of the present patent application, the Fig. 15B A method of mixing a first liquid and a first powder and a second liquid and a second powder using a syringe assembly and a vial assembly.
[0133] Fig.16 According to one embodiment of the present patent application, a Figure 2 The distal end of the syringe assembly Fig. 9 A cross-sectional view of a sealant delivery assembly of a sealant applicator.
[0134] Fig.17 is a perspective view of components of a sealant delivery system including a syringe assembly, a vial assembly, and a sealant delivery system having a spray tip according to one embodiment of the present patent application.
[0135] Fig.18 yes Fig.17 A perspective view of the syringe assembly is shown.
[0136] Fig.19 yes Fig.18 Exploded view of the syringe assembly shown.
[0137] Fig. 20 According to one embodiment of the present patent application Fig.18 A perspective cut-away view of a syringe assembly is shown having an end cap secured to a distal end of a syringe assembly housing.
[0138] Fig.21 Shown after the end cap has been removed to expose the distal end of the syringe assembly housing Fig. 20 A perspective cutaway view of a syringe assembly is shown.
[0139] Fig.22AAccording to one embodiment of the present patent application, Fig.18 The distal end of the syringe assembly is Fig.17 Stages of a method of coupling a proximal end of a vial assembly.
[0140] Fig. 22B The syringe assembly is shown after the distal end of the syringe assembly has been coupled to the proximal end of the vial assembly. Fig.22A Syringe assembly and vial assembly.
[0141] Fig. 22C According to one embodiment of the present patent application, the Fig. 22B A method of mixing a first liquid and a first powder and a second liquid and a second powder using a syringe assembly and a vial assembly.
[0142] Fig.23A yes Fig.17 A perspective view of the seal delivery assembly is shown.
[0143] Fig. 23B yes Fig.23A A perspective view of the proximal end of the sealant delivery assembly is shown.
[0144] Fig.24 Yes Fig.23A and Fig. 23B The sealant delivery components and Fig.21 A perspective view of the sealant applicator of the syringe assembly. DETAILED DESCRIPTION
[0145] refer to Figure 1 In one embodiment, a sealant delivery system 100 for dispensing a tissue sealant (e.g., a hemostatic agent; a sealant for sealing air leaks during lung surgery) preferably includes a syringe assembly 102, a vial assembly 104, and a sealant delivery assembly 106. In one embodiment, the syringe assembly 102 may include a first syringe and a second syringe, whereby each syringe contains a liquid (e.g., a diluent; a buffer solution; a catalyst; an initiator; an activation fluid, etc.). In one embodiment, the vial assembly 104 may include a first vial and a second vial, whereby each vial contains a reactive powder component (e.g., a fibrinogen powder; a thrombin powder; a reactive synthetic powder; a cross-linking agent, etc.), as will be described in more detail herein.
[0146] refer to Figure 2 and Figure 3In one embodiment, the syringe assembly 102 preferably has a proximal end 108 and a distal end 110. In one embodiment, the syringe assembly 102 includes a double barrel plunger 112 having a first plunger rod 114A and a second plunger rod 114B. In one embodiment, the proximal ends of the first plunger rod 114A and the second plunger rod 114B are connected to a depressible thumb tab 116, which a surgical staff (e.g., a surgeon) can use to depress the plunger rods 114A, 114B in the direction DIR1 toward the distal end 110 of the syringe assembly 102 (e.g., to extrude one or more sealant precursors from the distal end of the syringe assembly).
[0147] In one embodiment, the syringe assembly 102 preferably includes a first plunger 118A fixed to the distal end of the first plunger rod 114A and a second plunger 118B fixed to the distal end of the second plunger rod 114B. The first plunger 118A and the second plunger 118B preferably have outer peripheries that form a fluid-tight seal with the inner surfaces of the first syringe barrel and the second syringe barrel, as will be described in more detail herein.
[0148] In one embodiment, the syringe assembly 102 preferably includes a syringe assembly housing 120 that includes a first housing component 122A and a second housing component 122B configured to be connected together. In one embodiment, the first housing component 122A and the second housing component 122B can be snap-fitted together.
[0149] In one embodiment, the syringe assembly housing 120 is preferably adapted to hold a first syringe 124A and a second syringe 124B. The first syringe 124A and the second syringe 124B are preferably configured to accommodate and be disposed in the vial assembly 104 ( Figure 1 ) of the first and second vials of the respective first and second vials (eg, a diluent; a buffer solution; a catalyst; an initiator; an activation fluid, etc.) for mixing the reactive powder components.
[0150] In one embodiment, the first syringe 124A is configured to receive the distal end of the first plunger rod 114A and the first plunger 118A fixed to the distal end of the first plunger rod. In one embodiment, the second syringe 124B is configured to receive the distal end of the second plunger rod 114B and the second plunger 118B fixed to the distal end of the second plunger rod.
[0151] refer to Figure 3In one embodiment, the distal end of the first syringe 124A has a first dispensing tip 126A having an opening for dispensing a first fluid in a first fluid chamber (not shown) of the first syringe, and the distal end of the second syringe 124B has a second dispensing tip 126B having an opening for dispensing a second fluid in a second fluid chamber (not shown) of the second syringe.
[0152] In one embodiment, syringe assembly 102 preferably includes first and second end caps 128A, 128B adapted to be releasably secured to first and second dispensing tips 126A, 126B at the distal ends of respective first and second syringes 124A, 124B.
[0153] In one embodiment, after the first and second end caps 128A, 128B are removed from the respective first and second dispensing tips 126A, 126B of the first and second syringes 124A, 124B, the thumb tab 116 may be moved in the direction DIR1 ( Figure 2 ) is pressed toward the distal end of the syringe assembly, thereby dispensing the first fluid and the second fluid (e.g., diluent; buffer solution; catalyst; initiator; activation fluid, etc.) contained in the fluid chambers of the corresponding first syringe 124A and the second syringe 124B from the first dispensing top 126A and the second dispensing top 126B.
[0154] refer to Figure 4A and Figure 4B In one embodiment, the syringe assembly 102 preferably includes a first syringe 124A and a second syringe 124B positioned side by side between the first housing portion 122A and the second housing portion 122B of the syringe assembly housing 120. The first syringe 124A preferably has a first fluid chamber 130A configured to receive a first liquid (e.g., a diluent; a buffer solution; a catalyst; an initiator; an activation fluid, etc.). The second syringe 124B preferably includes a second fluid chamber 130B configured to receive a second liquid (e.g., a diluent; a buffer solution; a catalyst; an initiator; an activation fluid, etc.). In one embodiment, the first fluid and the second fluid contained in the respective first fluid chamber 130A and the second fluid chamber 130B may have the same properties or different properties.
[0155] In one embodiment, the distal end of the double-barrel plunger 112 is preferably assembled with the proximal ends of the corresponding first syringe 124A and second syringe 124B, so that the first plunger 118A and the distal end of the first plunger rod 114A are inserted into the proximal end of the first syringe 124A, and the second plunger 118B and the distal end of the first plunger rod 114B are inserted into the proximal end of the second syringe 124B.
[0156] In one embodiment, first end cap 128A is preferably secured to first dispensing tip 126A of first syringe 124A, and second end cap 128B is preferably secured to second dispensing tip 126B of second syringe 124B. The end caps may remain on the dispensing tips during storage and prior to use, and may be removed from the covering of the end caps immediately prior to use during a surgical procedure.
[0157] In one embodiment, the first end cap 128A and the second end cap 128B can be removed from the distal end 110 of the syringe assembly 102 to expose the dispensing tips 126A, 126B located at the distal ends of the respective first syringes 124A and second syringes 124B. In one embodiment, the thumb tab 116 of the double-barrel plunger 112 can be pressed down in the distal direction DIR1 toward the distal end 110 of the syringe assembly 102 to dispense and / or squeeze out the first liquid and the second liquid (e.g., diluent; buffer solution; catalyst; initiator; activation fluid, etc.) contained in the first fluid chamber 130A and the second fluid chamber 130B of the respective first syringes 124A and second syringes 124B. In one embodiment, the first liquid and the second liquid are used to reconstitute and mix the powder components ( Figure 1 ).
[0158] As will be described in greater detail herein, in one embodiment, after the activation fluid is initially forced into the vial of the vial assembly, the thumb tab 116 and the double-barrel plunger 112 can be retracted in a proximal direction indicated as DIR2 to draw the solution and / or mixture of the activation fluid and powdered reaction components back into the fluid chambers 130A, 130B of the respective first and second syringes 124A, 124B for further mixing the activation fluid and powdered reaction components together.
[0159] Certain types of therapeutic components must be stored in powdered form because once they are mixed into a liquid or solution, they react rapidly and / or lose their effectiveness. These therapeutic components need to be reconstituted with a liquid (e.g., a diluent; a buffer solution; a catalyst; an initiator; an activation fluid, etc.) before they can be used in a patient. The first liquid and the second liquid in the syringe can be used to activate the reactive powdered components contained in the vial assembly to form a tissue sealant or hemostat that can be sprayed and / or extruded onto the tissue. In one embodiment, the first liquid is used to reconstitute the first reactive powder component (e.g., fibrinogen in powder form; a reactive synthetic powder; a cross-linking agent, etc.), and the second liquid is used to reconstitute the second reactive powder component (e.g., thrombin in powder form; a reactive synthetic powder; a cross-linking agent, etc.).
[0160] refer to Figure 5A and Figure 5B In one embodiment, the vial assembly 104 ( Figure 1 ) preferably includes a vial assembly housing 132 having a proximal end 134 and a distal end 136. In one embodiment, the vial assembly 104 desirably includes a first vial 138A and a second vial 138B that are configured to contain powdered reactive components that are mixed together using a liquid (e.g., a diluent; a buffer solution; a catalyst; an initiator; an activation fluid, etc.) contained within a first syringe and a second syringe of the syringe assembly. In one embodiment, the first vial 138A and the second vial 138B are preferably secured to the distal end 136 of the vial assembly housing 132. In one embodiment, the first vial 138A may contain a first reactive powder component (e.g., a fibrinogen powder; a reactive synthetic powder; a cross-linking agent, etc.), and the second vial 138B may contain a second reactive powder component (e.g., a thrombin powder; a reactive synthetic powder; a cross-linking agent, etc.). In one embodiment, the vial assembly 104 preferably includes a first puncture element 140A and a second puncture element 140B, wherein the first puncture element has a first puncture spike (not shown) aligned with the first vial opening at the proximal end of the first vial 138A, and the second puncture element has a second puncture spike (not shown) aligned with the second vial opening at the proximal end of the second vial 138B.
[0161] In one embodiment, the first puncture element 140A and the second puncture element 140B can move between a retracted position and an extended position. In one embodiment, the first puncture element and the second puncture element move independently of each other. In one embodiment, the first puncture element and the second puncture element move simultaneously with each other.
[0162] Vial assembly 104 is designed to maintain the first reactive powdered component and the second reactive powdered component isolated from each other during storage of the vial assembly and prior to using the powdered components to form a therapeutic solution (e.g., a tissue sealant; a hemostatic agent; a sealant for sealing air leaks during lung surgery).
[0163] refer to Figure 6 In one embodiment, the vial assembly 104 desirably includes a vial assembly housing 132 having a first housing component 142A and a second housing component 142B. In one embodiment, the first housing component 142A and the second housing component 142B are adapted to snap fit together to form the vial assembly housing. In one embodiment, when the first housing component 142A and the second housing component 142B are assembled together, the vial assembly housing 132 is adapted to accommodate the first piercing element 140A and the second piercing element 140B, whereby the first piercing element and the second piercing element are able to slide relative to the vial assembly housing between a retracted position and an extended position, as will be described in more detail herein.
[0164] In one embodiment, the vial assembly 104 preferably includes a first powder vial 138A having a proximal end 144A with a first vial opening 146A and a first sealing membrane 148A, which covers and / or seals the first vial opening 146A. During storage and before use, the first sealing membrane 148A preferably maintains the first powder (e.g., the first powdered reactive component) disposed in the first powder vial 138A in a dry state. The vial assembly 104 preferably includes a first sealing ring 150A having a central opening 152A, which is configured to receive a first piercing spike 154A protruding from the distal end of the first piercing element 140A. In one embodiment, the vial assembly 104 includes a first O-ring 156A that is inserted into the opening at the proximal end of the first puncture element 140A and a first O-ring retainer 158A that preferably retains the first O-ring 156A within the opening at the proximal end of the first puncture element 140A.
[0165] In one embodiment, the vial assembly 104 preferably includes a second powder vial 138B having a proximal end 144B with a second vial opening 146B and a second sealing membrane 148B, which covers and / or seals the second vial opening 146B. During storage and before use, the second sealing membrane 148B preferably maintains the second powder (e.g., the second powdered reactive component) disposed in the second powder vial 138B in a dry state. The vial assembly 104 preferably includes a second sealing ring 150B having a central opening 152B, which is configured to receive a second septum piercing spike 154B protruding from the distal end of the second piercing element 140B. In one embodiment, the vial assembly 104 includes a second O-ring 156B that is inserted into the opening at the proximal end of the second puncture element 140B and a second O-ring retainer 158B that preferably retains the second O-ring 156B within the opening at the proximal end of the second puncture element 140B.
[0166] In one embodiment, the first housing component 142A and the second housing component 142B of the vial housing 132 are molded components having guide channels 145A, 145B extending side by side between the proximal end and the distal end of the vial housing 132. The guide channels 145A, 145B are preferably configured to receive the respective first and second puncture elements 140A, 140B for guiding the sliding movement of the first and second puncture elements between the retracted position and the extended position. When the first and second puncture elements 140A, 140B are disposed in the vial housing 132, the first and second puncture elements 140A, 140B can slide and / or move between the retracted position and the extended position. In one embodiment, when the first and second piercing elements are in the extended position, the first and second piercing spikes 154A, 154B pierce the respective first and second sealing membranes 140A, 140B sealing the first and second vial openings 146A, 146B of the respective first and second vial openings 138A, 138B.
[0167] refer to Figure 7 In one embodiment, the vial assembly 104 preferably includes a first vial 138A secured to the distal end 136 of the vial assembly housing 132. A first sealing membrane 148A covers and / or seals a first vial opening 146A located at a proximal end 144A of the first vial 138A. The first piercing element 140A is assembled with the vial assembly housing 132 such that a first piercing spike 154A of the first piercing element 140A is aligned with the first sealing membrane 148A covering and / or sealing a first vial opening 146A of the first vial 138A.
[0168] In one embodiment, the vial assembly 104 preferably includes a second vial 138B secured to the distal end 136 of the vial assembly housing 132. The second sealing membrane 148B covers and / or seals a second vial opening 146B located at a proximal end 144B of the second vial 138B. The second piercing element 140B is assembled with the vial assembly housing 132 such that the second piercing spike 154B of the second piercing element 140B is aligned with the second sealing membrane 148B covering and / or sealing the second vial opening 146B of the second vial 138B.
[0169] In one embodiment, the vial assembly housing 132 preferably includes a first proximal protrusion 162A for locking and / or retaining the first piercing element 140A in a retracted position and a first distal protrusion 163A for locking and / or retaining the first piercing element in an extended position. In one embodiment, the first piercing element 140A preferably includes a first resilient flange 164A adapted to selectively engage the first proximal protrusion 162A and the first distal protrusion 163A. In one embodiment, when the first piercing element 140A is in the Figure 7 In the retracted position shown, the first resilient flange 164A desirably engages the first proximal protrusion 162A to hold the first puncture element 140A in the retracted position. In one embodiment, the first puncture element 140A can be slid and / or pressed down in the distal direction DIR1, whereupon the first resilient flange 164A is released from the first proximal protrusion 162A and slides into engagement with the first distal protrusion 163A to lock and / or hold the first puncture element 140A in the extended position ( Figure 8B ).
[0170] In one embodiment, the vial assembly housing 132 preferably includes a second proximal protrusion 162B for locking and / or holding the second piercing element 140B in the retracted position and a second distal protrusion 163B for locking and / or holding the second piercing element 140B in the extended position. In one embodiment, the second piercing element 140B preferably includes a second resilient flange 164B adapted to selectively engage the second proximal protrusion 162B and the second distal protrusion 163B. In one embodiment, when the second piercing element 140B is in the Figure 7 In the retracted position shown, the second elastic flange 164B engages the second proximal protrusion 162B to hold the second puncture element 140B in the retracted position. In one embodiment, the second puncture element 140B can be slid and / or pressed down in the distal direction DIR1, so that the second elastic flange 164B is released from the second proximal protrusion 162B and slides to engage with the second distal protrusion 163B for locking and / or holding the second puncture element 140B in the extended position ( Figure 8B ).
[0171] In one embodiment, when the first piercing element 140A is assembled with the vial assembly housing 132, the first piercing spike 154A is aligned with the first sealing membrane 148A sealing the first vial opening 146A of the first vial 138A. Figure 8B ), the first piercing spike 154A pierces the first sealing membrane 148A to provide a syringe 124A ( Figure 4A ) and a first powder (e.g., a first powdered reactive component) contained in a first powder chamber 160A of a first vial 138A.
[0172] In one embodiment, when the second piercing element 140B is assembled with the vial assembly housing 132, the second piercing spike 154B is aligned with the second sealing membrane 148B that seals the second vial opening 146B of the second vial 138B. Figure 8B ), the second piercing spike 154B pierces the second sealing membrane 148B to provide a second piercing spike 154B ( Figure 4A ) and a second powder (e.g., a second powdered reactive component) contained in a second powder chamber 160B of a second vial 138B.
[0173] In one embodiment, the first piercing element 140A has an elongated conduit defining a first fluid passage extending through both the first piercing element and the first piercing spike 154A for providing fluid communication between the first fluid chamber of the first syringe and the powder chamber 160A of the first vial 138A, which enables the first liquid to be used to reconstitute the first powder disposed within the first vial. In one embodiment, the first O-ring 156A is inserted into the opening at the proximal end of the first piercing element 140A, and the first O-ring retainer 158A retains the first O-ring 156A within the proximal opening of the first piercing element 140A.
[0174] In one embodiment, the second piercing element 140B has an elongated conduit defining a second fluid passage extending through both the second piercing element and the second piercing spike 154B for providing fluid communication between the second fluid chamber of the second syringe and the second powder chamber 160B of the second vial 138B, which enables the second liquid to be used to reconstitute the second powder (e.g., a second powdered reactive component) disposed within the second vial. In one embodiment, a second O-ring 156B is inserted into the opening at the proximal end of the second piercing element 140B, and a second O-ring retainer 158B retains the second O-ring 156B within the proximal opening of the second piercing element 140B.
[0175] refer to Fig. 8A In one embodiment, the vial assembly 104 preferably includes a first vial 138A and a second vial 138B secured to the distal end 136 of the vial assembly housing 132. In one embodiment, the first vial 138A includes a first powder chamber 160A configured to hold a first powder (e.g., a first powdered reactive component; fibrinogen powder; thrombin powder; a cross-linking agent, etc.), and the second vial 138B includes a second powder chamber 160B configured to hold a second powder (e.g., a second reactive powder; fibrinogen powder; thrombin powder; a cross-linking agent, etc.). Fig. 8A 148A. The first piercing element 140A is in a retracted position, wherein the first piercing spike 154A is located proximal to the first sealing membrane 148A. The first piercing element 140A includes a first resilient flange 164A that engages a first proximal protrusion 162A of the vial housing 132 for holding the first piercing element 140A in the retracted position. The vial assembly 104 includes a first distal protrusion 163A that is adapted to engage a distal end of the first resilient flange 164A for holding the first piercing element 140A in an extended configuration, as will be described in more detail herein.
[0176] In one embodiment, the second piercing element 140B is in a retracted position, wherein the second piercing spike 154B is located proximal to the second sealing membrane 148B. The second piercing element 140B includes a second resilient flange 164B that engages a second proximal protrusion 162B of the vial housing 132 for holding the second piercing element 140B in the retracted position. The vial assembly 104 includes a second distal protrusion 163B that is adapted to engage a distal end of the second resilient flange 164B for holding the second piercing element 140B in an extended configuration, as will be described in more detail herein.
[0177] refer to Figure 8BIn one embodiment, the first puncture element 140A and the second puncture element 140B can be advanced in the distal direction DIR1 toward the distal end 136 of the vial assembly housing 132 for moving the first puncture element and the second puncture element to the extended position. Figure 8B In the extended position shown, the first piercing spike 154A pierces the first sealing membrane 148A, and the second piercing spike 154B pierces the second sealing membrane 148B. The first resilient flange 162A of the first piercing element 140A engages the first distal protrusion 163A of the vial assembly housing 132 for holding and / or locking the first piercing element 140A in the extended position, and the second resilient flange 162B of the second piercing element 140B engages the second distal protrusion 163B of the vial assembly housing 132 for holding and / or locking the second piercing element 140B in the extended position.
[0178] refer to Fig. 9 and Fig.10 In one embodiment, the sealant delivery system 100 ( Figure 1 ) of the sealant delivery assembly 106 preferably includes a proximal end 168 and a distal end 170, the proximal end being configured to be coupled to the syringe assembly 102 ( Figure 1 ) is connected to a distal end of the sealant delivery assembly 106 that is suitable for extruding and / or spraying a tissue sealant (e.g., a hemostat; a sealant used to seal air leaks during lung surgery). In one embodiment, the proximal end 168 of the sealant delivery assembly 106 desirably includes a sealant delivery assembly housing 172 having a first housing component 172A and a second housing component 172B that can be snap-fitted together.
[0179] In one embodiment, the housing 172 preferably includes an H-type connector 174 having a first hub 176A adapted to receive a first O-ring 178A and a first O-ring retainer 180A. In one embodiment, the first hub 176A, the first O-ring 178A, and the first O-ring retainer 180A are preferably aligned with a first fluid passageway that is located between the first syringe 124A ( Figure 4A ) provides fluid communication between the first fluid compartment 130A and the distal end of the sealant delivery assembly 106.
[0180] In one embodiment, the H-type connector 174 preferably includes a second hub 176B adapted to receive a second O-ring 178B and a second O-ring retainer 180B. In one embodiment, the second hub 176B, the second O-ring 178B, and the second O-ring retainer 180B are preferably aligned with the second fluid passageway, which is located in the second syringe 124B ( Figure 4A) provides fluid communication between the second fluid compartment 130B and the distal end of the sealant delivery assembly 106.
[0181] In one embodiment, the sealant delivery assembly 106 preferably includes a cannula 182 (e.g., a rigid tube) adapted to receive a first flexible tube 184A and a second flexible tube 184B. The cannula can be rigid and can be made of a biocompatible material, such as metal and polymer. The first flexible tube 184A preferably has a proximal end in fluid communication with the first hub 176A of the H-type connector 174. The second flexible tube 184B preferably has a proximal end in fluid communication with the second hub 176B of the H-type connector 174.
[0182] In one embodiment, the sealant delivery assembly 106 desirably includes a ductile connector 186 that is secured to the distal end of the cannula 182. The sealant delivery assembly 106 preferably includes a spray tip 188 secured to the distal end of the ductile connector 186. The spray tip 188 may house a static mixer for mixing the first precursor solution and the second precursor solution directed into the spray tip 188 together.
[0183] refer to Fig.11 , in one embodiment, the proximal end of the elongated cannula 182 is assembled with the distal end of the sealant delivery assembly housing 172. The first flexible tube 184A and the second flexible tube 184B extend through the elongated conduit of the cannula 182. The proximal end of the first flexible tube 184A is in fluid communication with the first hub 176A. The proximal end of the second flexible tube 184B is in fluid communication with the second hub 176B. The first O-ring 178A is inserted into the first hub 176A and is held in place by the first O-ring retainer 180A. The second O-ring 178B is inserted into the second hub 176B and is held in place by the second O-ring retainer 180B.
[0184] refer to Fig.12 In one embodiment, a ductile connector 186 at the distal end of the sealant delivery assembly 106 preferably couples the spray tip 188 with the distal end of the cannula 182. The ductile connector 186 desirably includes a ductile member 190 (e.g., a ductile metal rod; a ductile pin) disposed therein that enables the spray tip 188 to be positioned and retained at different angles relative to the longitudinal axis A1 of the cannula 182.
[0185] In one embodiment, the spray tip 188 preferably includes a spray tip housing 192 that houses a static mixer 194 having mixing fins 195. The first precursor solution and the second precursor solution delivered to the spray tip 188 via the first flexible tube 184A and the second flexible tube 184B are preferably mixed together within the spray tip housing 194 by the mixing fins 195 of the static mixer 192. The mixed precursor solution can be extruded and / or sprayed from the distal end of the sealant applicator via the extrusion opening 196 of the spray cap 197, which is located at the distal end 170 of the sealant delivery assembly 106. In one embodiment, the sealant delivery assembly 106 and the spray cap may include one or more structural features (e.g., vortex chambers) disclosed in commonly assigned U.S. Patent Application Publication 2021 / 0101162 to Trezza II et al. (Attorney Docket No. ETH6050USNP1), the disclosure of which is incorporated herein by reference.
[0186] refer to Fig.13A In one embodiment, the vial assembly 104 includes a vial assembly housing 132, wherein a first vial 138A and a second vial 138B are secured to a distal end 136 of the vial assembly housing 132. The first vial 138A contains a first reactive powder component (e.g., fibrinogen powder; reactive synthetic powder; cross-linking agent, etc.), and the second vial 138B contains a second reactive powder component (e.g., thrombin powder; reactive synthetic powder; cross-linking agent, etc.).
[0187] refer to Fig. 13B In one embodiment, the first puncture element 140A and the second puncture element 140B can be advanced in the distal direction DIR1 toward the distal end 136 of the vial assembly housing 132 to move the first puncture element and the second puncture element to a position such as Figure 8B In the extended position, the first and second piercing spikes 154A, 154B of the respective first and second piercing elements pierce the respective first and second sealing membranes 148A, 148B ( Figure 8B ).
[0188] refer to Fig.14 In one embodiment, by removing first end cap 128A and second end cap 128B, syringe assembly 102 containing first liquid and second liquid for reconstitution of reactive powder components can be ready for connection to the proximal end of vial assembly housing 132 ( Fig. 13B). Removal of first and second end caps 128A, 128B exposes respective first and second dispensing tips 126A, 126B accessible at the distal end of syringe assembly housing 120.
[0189] refer to Fig.15A In one embodiment, between the first end cap 128A and the second end cap 128B ( Fig.14 ) has been removed from the distal end of syringe assembly housing 120 of syringe assembly 102, the distal end of syringe assembly housing 120 is preferably coupled to proximal end 134 of vial assembly housing 132. First dispensing tip 126A is preferably inserted into the opening at the proximal end of first piercing element 140A, and second dispensing tip 126B is preferably inserted into the opening at the proximal end of second piercing element 140B.
[0190] refer to Fig. 15B After the vial assembly 104 has been assembled with the distal end of the syringe assembly 102, the first syringe 124A ( Figure 4A ) is preferably in fluid communication with a first powder (e.g., a powdered reactive component) disposed in a first powder chamber 160A of the first vial 138A. Similarly, a second syringe 124B ( Figure 4A ) is preferably in fluid communication with a second powder (e.g., a powdered reactive component) disposed in a second powder chamber 160B of a second vial 138B.
[0191] Fig. 15CThe distal end of the syringe assembly 102 connected to the proximal end of the vial assembly 104 is shown. The syringe assembly includes a first syringe 124A having a first fluid chamber 130A containing a first activating fluid (e.g., a diluent; a buffer solution; a catalyst; an initiator; an activating fluid that activates a first powder, etc.). The syringe assembly 102 also desirably includes a second syringe barrel 124B having a second fluid chamber 130B containing a second activating fluid (e.g., a diluent; a buffer solution; a catalyst; an initiator; an activating fluid that activates a second powder, etc.). The first syringe barrel 124A is connected to the proximal end of the vial assembly 104 so that the first dispensing tip 128A of the first syringe barrel 124A is aligned with and in fluid communication with the first vial opening 146A of the first vial 138A. The first vial 138A has a first powder chamber 160A containing a first powder, which is to be reconstituted using the first activating fluid disposed in the first fluid chamber 130A of the first syringe barrel 124A. The second dispensing tip 128B at the distal end of the second syringe 124B is preferably aligned with the second vial opening 146B of the second vial 138B. The second vial 138B preferably contains a second powder chamber 160B having a second powder to be reconstituted using a second activation fluid disposed within the second fluid chamber 130B of the second syringe 124B.
[0192] exist Fig. 15C During the stages shown, the first liquid and the first powder are kept isolated from the second liquid and the second powder.
[0193] In one embodiment, the first activation fluid in the first syringe 124A is mixed with the first powder in the first vial 138A by advancing and retracting the double barrel plunger 112 in the distal and proximal directions. When the first plunger rod 114A is advanced toward the distal end of the syringe housing 120, the first activation fluid in the first fluid chamber 130A of the first syringe 124A is forced into the first powder chamber 160A of the first vial 138A for reconstitution of the first powder into a first therapeutic solution. When the first plunger rod 114A is retracted from the distal end of the syringe housing 120, the first therapeutic solution of the first powder and the first activation fluid is drawn back into the first fluid chamber 130A of the first syringe 124A. The first plunger rod 114A can reciprocate back and forth between an extended position and a retracted position for thoroughly mixing the first activation fluid and the first powder to form a first precursor solution (e.g., a flowable liquid). In one embodiment, after the first precursor solution has been formed, the first plunger rod 114A is preferably fully retracted to draw the entire volume of the first precursor solution into the first fluid chamber 130A of the first syringe 124A.
[0194] In one embodiment, the second activation fluid in the second syringe 124B is mixed with the second powder in the second vial 138B by advancing and retracting the double barrel plunger 112 in the distal and proximal directions. When the second plunger rod 114B is advanced toward the distal end of the syringe assembly housing 120, the second activation fluid in the second fluid chamber 130B of the second syringe 124B is forced into the second powder chamber 160B of the second vial 138B for reconstitution of the second powder into a second therapeutic solution. When the second plunger rod 114B is retracted from the distal end of the syringe assembly housing 120, the second powder and the second therapeutic solution of the second activation fluid are drawn back into the second fluid chamber 130B of the second syringe 124B. The second plunger rod 114B can reciprocate back and forth between an extended position and a retracted position for thoroughly mixing the second activation fluid and the second powder to form a second precursor solution (e.g., a flowable liquid). In one embodiment, after the second precursor solution has been formed, the second plunger rod 114B is preferably fully retracted to draw the entire volume of the second precursor solution into the second fluid chamber 130B of the second syringe 124B.
[0195] refer to Fig. 15C and Fig.16 In one embodiment, after the first and second precursor solutions have been generated and drawn into the first and second fluid chambers 130A, 130B of the respective first and second syringes 124A, 124B of the syringe assembly 102, the vial assembly 104 may not be coupled to the distal end of the syringe assembly housing 120, and the sealant delivery assembly 106 may be secured to the distal end of the syringe assembly housing 120 for extruding the first and second precursor solutions from the distal end of the sealant applicator. In one embodiment, the sealant delivery assembly housing 172 at the proximal end of the sealant delivery assembly 106 is preferably connected to the distal end of the syringe assembly housing 120. The cannula 182 and the spray tip 188 preferably extend toward the distal end 170 of the sealant delivery assembly 106.
[0196] After the sealant delivery assembly has been secured to the distal end of the syringe assembly housing, the first fluid chamber 130A containing the first precursor of the first syringe 124A is preferably in fluid communication with the spray tip 188 via the first flexible tube 184A. The second fluid chamber 130B containing the second precursor of the second syringe 124B is preferably in fluid communication with the spray tip 188 via the second flexible tube 184B.
[0197] In one embodiment, the double barrel plunger 112 is depressed in the distal direction indicated as DIR1 to force the first body solution and the second precursor solution to flow out of the first fluid chamber 130A and the second fluid chamber 130B of the corresponding first syringe 124A and the second syringe 124B, whereupon the first precursor solution and the second precursor solution flow through the corresponding first flexible tube 184A and the second flexible tube 184B until they reach the injection tip 188. After reaching the injection tip, the first precursor solution and the second precursor solution are injected into the injection nozzle 188 through the static mixer 194 ( Fig.12 ) mixes the first precursor solution and the second precursor solution together, whereupon the first precursor solution and the second precursor solution react with each other to form a tissue sealant or hemostatic agent that is ejected from a jet cap 197 ( Fig.12 ) is extruded through the dispensing opening 196.
[0198] refer to Fig.17 In one embodiment, the sealant delivery system 200 preferably includes a syringe assembly 202 containing one or more liquids or fluids for reconstituting the therapeutic powder, a vial assembly 204 having a first vial 238A and a second vial 238B containing the powdered reactive component, and a sealant delivery assembly 206 for extruding the sealant or hemostatic agent. In one embodiment, the syringe assembly 202 can be a molded component having side-by-side dual barrel cavities configured to hold liquids for reconstituting the reactive powdered components. In one embodiment, the vial assembly 204 can be similar to the vial assembly 206 described above in FIG. 5A to FIG. 5B , Figure 6 , Figure 7 and FIG. 8A to FIG. 8B In one embodiment, the sealant delivery assembly 206 may be similar to the one described above in Figures 9 to 12 The sealant delivery assembly 106 shown and described in FIG.
[0199] refer to Fig.18 In one embodiment, the syringe assembly 202 preferably includes a syringe assembly housing 220 adapted to receive a distal end of a double barrel plunger 212. The double barrel plunger 212 preferably includes a first plunger rod 214A insertable into a first syringe barrel cavity formed in the syringe assembly housing 220 of the syringe assembly 202 and a second plunger rod 214B insertable into a second syringe barrel cavity of the syringe assembly housing 220 of the syringe assembly 202. In one embodiment, the proximal end of the first syringe plunger rod 214A and the proximal end of the second syringe plunger rod 214B are interconnected by a thumb tab 216 defining the proximal end of the double barrel plunger 212.
[0200] In one embodiment, the syringe assembly 202 preferably includes a syringe end cap 228 which is releasably secured to the distal end of the syringe assembly housing 220 of the syringe assembly 202 for covering a syringe dispensing tip that is fluidically connected to a corresponding syringe barrel cavity formed in the syringe assembly housing 220, as will be described in more detail herein.
[0201] refer to Fig.19 , the syringe assembly 202 preferably includes a syringe assembly housing 220 having a proximal end adapted to receive the double barrel plunger 212 and a distal end adapted to be connected to a syringe end cap 228. The syringe assembly housing 220 preferably includes a first dispensing tip 226A that protrudes from the distal end of the syringe housing 220 and is in fluid communication with a first fluid chamber of a first syringe barrel cavity integrally formed within the syringe assembly housing 220. The syringe assembly housing 220 preferably includes a second dispensing tip 226B that protrudes from the distal end of the syringe housing 220 and is in fluid communication with a second fluid chamber of a second syringe barrel cavity integrally formed within the syringe assembly housing 220.
[0202] In one embodiment, the syringe end cap 228 can be disconnected from the distal end of the syringe assembly housing 220 to expose the first dispensing tip 226A and the second dispensing tip 226B. After the syringe end cap 228 has been removed to expose the dispensing tips 226A, 226B, the distal end of the syringe assembly housing can be assembled with a vial assembly or a sealant delivery assembly.
[0203] In one embodiment, the double barrel plunger 212 preferably includes a first plunger rod 214A having a distal end adapted to be connected to the first plunger 218A. The double barrel plunger 212 also includes a second plunger rod 214B having a distal end adapted to be connected to the second plunger 218B. In one embodiment, the distal end of the first plunger rod 214A on which the first plunger 218A is fixed can be inserted into a first fluid chamber defined by a first syringe barrel cavity of the syringe assembly housing, and the distal end of the second plunger rod 214B on which the second plunger 218B is fixed is inserted into a second fluid chamber defined by a second syringe barrel cavity of the syringe assembly housing.
[0204] refer to Fig. 20In one embodiment, the distal ends of the first plunger 218A and the first plunger rod 214A are inserted into the first fluid chamber 230A of the first syringe barrel cavity 224A integrally formed in the syringe assembly housing 220 of the syringe assembly 202. In a similar manner, the distal ends of the second plunger 218B and the second plunger rod 214B are inserted into the second fluid chamber 230B of the second syringe barrel cavity integrally formed in the syringe assembly housing 220 of the syringe assembly 202. In one embodiment, a first liquid (e.g., a diluent; a buffer solution; a catalyst; an initiator; an activating fluid, etc.) is disposed in the first fluid chamber 230A of the first syringe barrel cavity 224B. In one embodiment, a second liquid (e.g., a diluent; a buffer solution; a catalyst; an initiator; an activating fluid, etc.) is disposed in the second fluid chamber 230B of the second syringe barrel cavity 224B. The first activating fluid and the second activating fluid may have the same properties or different properties.
[0205] In one embodiment, during storage, the syringe assembly end cap 228 is preferably connected to the distal end of the syringe assembly housing 220 of the syringe assembly 202 to cover the first dispensing tip 226A and the second dispensing tip 226B that are in fluid communication with the corresponding first fluid chamber 230A and the second fluid chamber 230B.
[0206] refer to Fig.21 In one embodiment, the syringe assembly end cap 228 ( Fig. 20 ) is removable from the distal end of the syringe assembly housing 220 to cover the syringe dispensing tips 226A, 226B that are in fluid communication with the first fluid chamber 230A and the second fluid chamber 230B of the respective first syringe barrel chamber 224A and the second syringe barrel chamber 224B.
[0207] refer to Fig.22A In one embodiment, the syringe end cap 228 ( Fig. 20 ) has been removed from the distal end of syringe assembly housing 220 of syringe assembly 202, the distal end of syringe assembly housing 220 may be coupled to proximal end 234 of vial assembly housing 232 of vial assembly 204. First syringe dispensing tip 226A is preferably inserted into the opening at the proximal end of first piercing element 240A for use in first fluid chamber 230A ( Fig.21 ) and the first vial 238A. The second syringe dispensing tip 226B is preferably inserted into the opening at the proximal end of the second piercing element 240B for injecting fluid into the second fluid chamber 230B ( Fig.21 ) provides fluid communication between the vial and the second vial 238B.
[0208] refer to Fig. 22BAfter the vial assembly 204 has been assembled with the distal end of the syringe assembly housing 220 of the syringe assembly 202, the first syringe barrel cavity 224A ( Fig.21 ) is preferably connected to the first powder fluid in the first powder chamber 260A of the first vial 238A of the vial assembly 204. Similarly, the second syringe barrel cavity 224B ( Fig.21 ) in the second fluid chamber 230B (e.g., a diluent; a buffer solution; a catalyst; an initiator; an activation fluid; a reconstitution fluid, etc.) is preferably connected to the second powder fluid in the second powder chamber 260B of the second vial 238B disposed in the vial assembly 204.
[0209] refer to Fig. 22C In one embodiment, the distal end of the syringe assembly 202 is connected to the proximal end of the vial assembly 204. The syringe assembly includes a first syringe barrel cavity 224A having a first fluid chamber 230A for accommodating a first liquid for reconstitution of a first powder. The first syringe barrel cavity 224A is connected to the proximal end of the vial assembly 204 so that the first dispensing top 226A of the first syringe barrel cavity 224A is aligned with and in fluid communication with the first vial opening 246A of the first vial 238A. The first vial 238A has a first powder chamber 260A for accommodating a first powder, which is to be reconstituted using the first liquid disposed in the first fluid chamber 230A of the first syringe barrel cavity 224A.
[0210] In one embodiment, syringe assembly 202 desirably includes a second syringe barrel cavity 224B having a second fluid chamber 230B containing a second liquid for reconstructing a second powder. A second dispensing tip 226B at the distal end of second syringe barrel cavity 224B is preferably aligned with a second vial opening 246B of a second vial 238B. Second vial 238B preferably includes a second powder chamber 260B containing a second powder, which will be reconstituted using a second liquid disposed in the second fluid chamber 230B of second syringe barrel cavity 224B.
[0211] In one embodiment, by advancing and retracting the double barrel plunger 112 in the distal direction DIR1 and the proximal direction DIR2, the first liquid in the first fluid chamber 230A of the first syringe barrel cavity 224A is mixed with the first powder in the first powder compartment 260A disposed in the first vial 138A. When the first plunger rod 114A is advanced distally toward the distal end of the syringe assembly housing 220 in the direction DIR1, the first liquid in the first fluid chamber 230A of the first syringe barrel cavity 224A is forced into the first powder chamber 260A of the first vial 238A. When the first plunger rod 214A is retracted from the distal end of the syringe assembly housing 220, the first precursor solution including the first powder and the first liquid is drawn back into the first fluid chamber 230A of the first syringe barrel cavity 224A. The first plunger rod 214A can reciprocate back and forth between the extended position and the retracted position for thoroughly mixing the first liquid and the first powder component to form a first precursor solution (e.g., a flowable liquid). In one embodiment, after the first precursor solution has been generated, the first plunger rod 214A is preferably fully retracted to draw the entire volume of the first precursor solution back into the first fluid chamber 230A of the first syringe barrel cavity 224A.
[0212] In one embodiment, by advancing and retracting the double barrel plunger 112 in the distal direction (DIR1) and the proximal direction (DIR2), the second liquid contained in the second syringe barrel cavity 224B can be mixed with the second powder in the second powder component 260B disposed in the second vial 138B. When the second plunger rod 114B is advanced toward the distal end of the syringe assembly housing 220, the second liquid in the second fluid chamber 230B of the second syringe barrel cavity 224B is forced into the second powder chamber 260B of the second vial 238B for reconstructing the second powder into a second precursor solution. When the second plunger rod 214B is retracted from the distal end of the syringe assembly housing 220, the second precursor solution including the second powder and the second liquid is drawn back into the second fluid chamber 230B of the second syringe barrel cavity 224B. The second plunger rod 214B can reciprocate back and forth between the extended position and the retracted position for thoroughly mixing the second liquid and the second powder to form a second precursor solution (e.g., a flowable liquid). In one embodiment, after the second precursor solution has been formed, the second plunger rod 214B is preferably fully retracted to draw the entire volume of the second precursor solution back into the second fluid chamber 230B of the second syringe barrel cavity 224B.
[0213] In one embodiment, the first precursor solution and the second precursor solution may be mixed together to form a tissue sealant or hemostat that is applied to tissue during a surgical procedure, such as a minimally invasive surgical procedure.
[0214] refer to Fig. 22C , FIG. 23A to FIG. 23B and Fig.24 In one embodiment, after the first precursor solution and the second precursor solution have been generated and drawn into the first fluid chamber 230A and the second fluid chamber 230B of the respective first syringe barrel chamber 224A and the second syringe barrel chamber 224B, the vial assembly 204 ( Fig. 22C ) may not be coupled to the distal end of the syringe assembly housing 220 to expose the first dispensing tip 226A and the second dispensing tip 226B ( Fig. 22C In one embodiment, the sealant delivery assembly housing 272 at the proximal end of the sealant delivery assembly 206 is preferably coupled to the distal end of the syringe assembly housing 220. The cannula 282 and the spray tip 288 preferably extend toward the distal end 270 of the sealant delivery assembly 206.
[0215] After the sealant delivery assembly 206 has been secured to the distal end of the syringe assembly housing 220, the first fluid chamber 230A of the first syringe cavity 224A containing the first precursor solution is preferably opened via a first fluid passageway (e.g., Fig.11 The first flexible tube 184A shown in FIG. 1 is in fluid communication with the spray tip 288. The second fluid chamber 230B containing the second precursor solution of the second syringe chamber 224B is preferably connected to the second fluid passage (e.g., Fig.11 The second flexible tube 184B) shown in FIG. 1 is in fluid communication with the spray tip 288.
[0216] refer to Fig.23A and Fig. 23B In one embodiment, similar to the above Fig. 9 and Fig.10 The sealant delivery assembly 206 shown and described in the drawings preferably includes an elongated cannula 282 having a proximal end and a distal end. The sealant delivery assembly housing 272 is secured to the proximal end of the cannula 282, and the spray tip 288 is secured to the distal end of the cannula 282 via a ductile connector 286. The ductile connector 286 desirably enables the spray tip 282 to articulate to different angles relative to the longitudinal axis A1 of the elongated cannula 282. The ductile connector may include a ductile rod or pin that maintains its shape after being bent into a particular orientation, which in turn holds the spray tip 282 in a selected orientation ( Fig.24 ).
[0217] refer to Fig. 23B and Fig.24In one embodiment, the proximal end of the sealant delivery assembly housing 272 of the sealant delivery assembly 206 is connected to the distal end of the syringe assembly housing 220 of the syringe assembly 202. In one embodiment, the first dispensing tip 226A ( Fig. 22C ) is inserted into the first hub 276A at the proximal end of the sealant delivery assembly housing 272. The second dispensing tip 226B ( Fig. 22C ) is inserted into the second hub 276B at the proximal end of the sealant delivery assembly housing 272.
[0218] In one embodiment, the spray tip 288 is coupled to the distal end of the cannula 282 via a ductile connector 286. The ductile connector 286 enables the spray tip 288 to be positioned at different angles relative to the longitudinal axis A1 of the elongated cannula 282 of the sealant delivery assembly 206.
[0219] refer to Fig.24 In one embodiment, the distal end of the sealant delivery assembly 206 may have the same Fig.12 The ductile connector 286 couples the spray tip 288 to the distal end of the cannula 282. The ductile connector 286 preferably includes an elongated ductile member (e.g., Fig.12 The ductile member enables the spray tip 288 to be positioned at different angles relative to the longitudinal axis A1 of the cannula 282.
[0220] In one embodiment, the dual barrel plunger 212 is depressed in a distal direction indicated as DIR1 to force the first precursor solution and the second precursor solution from the first fluid chamber 230A and the second fluid chamber 230B ( 230B ) of the respective first syringe barrel chamber 224A and the second syringe barrel chamber 224B. Fig. 22C ) flows out, whereupon the first precursor solution and the second precursor solution flow toward the spray tip 288 so as to be mixed together within the spray tip and extruded from the distal end 270 of the sealant delivery assembly 206.
[0221] In one embodiment, the sealant delivery system maintains the first precursor solution and the second precursor solution isolated from each other until they are mixed together within the spray tip 288. When mixed together within the spray tip 288, the first precursor solution and the second precursor solution preferably react with each other to form a sealant or hemostat that controls bleeding. The sealant or hemostat is preferably sprayed onto the tissue in a fluid form, whereupon the interacting first precursor solution and the second precursor solution solidify, coagulate, and / or gel to stop or control bleeding.
[0222] Although the foregoing is directed to embodiments of the present invention, other and further embodiments of the present invention may be devised without departing from the basic scope of the present invention, which is limited only by the scope of the following claims. For example, the present invention contemplates that any feature shown in any embodiment described herein or incorporated by reference may be combined with any feature shown in any other embodiment described herein or incorporated by reference and still fall within the scope of the present invention.
Claims
1. A sealant delivery system, comprising: a syringe assembly including a first syringe and a second syringe side-by-side, the first syringe having a first fluid chamber and the second syringe having a second fluid chamber; a vial assembly coupled to a distal end of the syringe assembly, the vial assembly comprising a first vial and a second vial arranged side by side; the first vial having a proximal end aligned with the distal end of the first syringe, the first vial including a first vial opening closed at the proximal end thereof by a first sealing membrane; the second vial having a proximal end aligned with the distal end of the second syringe, the second vial including a second vial opening closed at the proximal end thereof by a second sealing membrane; The vial assembly includes a first piercing element, the first piercing element is located between the distal end of the first syringe and the proximal end of the first vial, the first piercing element has a first piercing spike protruding from the distal end thereof, the first piercing element is movable between a retracted position and an extended position, in which the first piercing spike is located on the proximal side of the first sealing membrane, and in the extended position, the first piercing spike passes through the first sealing element to pierce the first sealing membrane to provide a first fluid communication between the first fluid chamber of the first syringe and the first vial; and The vial assembly includes a second piercing element, which is located between the distal end of the second syringe and the proximal end of the second vial, and the second piercing element has a second piercing spike protruding from its distal end. The second piercing element can be moved between a retracted position and an extended position. In the retracted position, the second piercing spike is located on the proximal side of the second sealing membrane. In the extended position, the second piercing spike passes through the second sealing element to pierce the second sealing membrane to provide a second fluid connection between the second fluid chamber of the second syringe and the second vial.
2. The sealant delivery system of claim 1, further comprising: The first piercing element defines a first fluid passage extending along a length thereof for providing the first fluid communication between the first fluid chamber of the first syringe and the first vial; and The second piercing element defines a second fluid passage extending along a length thereof for providing the second fluid communication between the second fluid chamber of the second syringe and the second vial.
3. The sealant delivery system of claim 2, wherein the first fluid pathway and the second fluid pathway are isolated from each other, and wherein the syringe assembly and the vial assembly can only be connected together in one configuration to ensure that the first syringe always mates with the first vial and the second syringe always mates with the second vial.
4. The sealant delivery system of claim 1, further comprising: a first liquid disposed in the first fluid chamber of the first syringe; a first powdered reactive component disposed within the first vial, wherein the first liquid and the first powdered reactive component are configured to be mixed together to reconstitute the first powdered reactive component to form a first therapeutic solution; a second liquid disposed in the second fluid chamber of the second syringe; A second powdered reactive component is disposed within the second vial, wherein the second liquid and the second powdered reactive component are configured to be mixed together to reconstitute the second powdered reactive component to form a second therapeutic solution.
5. The sealant delivery system of claim 1, wherein the vial housing further comprises: a first guide channel extending between a proximal end and a distal end of the vial housing, wherein the first piercing element is disposed in the first guide channel and is configured to move between the retracted position and the extended position; A second guide channel extends between the proximal end and the distal end of the vial housing, wherein the second piercing element is disposed in the second guide channel and is configured to move between the retracted position and the extended position.
6. The sealant delivery system of claim 5, wherein the vial housing further comprises: a first proximal projection extending into the first guide channel, the first proximal projection being adapted to contact the first puncture element to retain the first puncture element in the retracted position; a first distal protrusion extending into the first guide channel, the first distal protrusion being adapted to contact the first puncture element to maintain the first puncture element in the extended position; a second proximal projection extending into the second guide channel, the second proximal projection being adapted to contact the second puncture element to retain the second puncture element in the retracted position; A second distal protrusion extends into the first guide channel, the second distal protrusion being adapted to contact the first puncture element to maintain the first puncture element in the extended position.
7. The sealant delivery system of claim 6, further comprising: the first piercing element comprising a first resilient flange adapted to sequentially engage the first proximal projection and the first distal projection of the vial housing when the first piercing element is moved from the retracted position to the extended position within the first guide channel; The second piercing element includes a second resilient flange adapted to sequentially engage the second proximal protrusion and the second distal protrusion of the vial housing when the second piercing element is moved from the retracted position to the extended position within the second guide channel.
8. The sealant delivery system of claim 1 , further comprising: The first puncture element has a central opening at its proximal end; The first syringe has a first dispensing tip protruding from the distal end thereof, the first dispensing tip being inserted into the central opening at the proximal end of the first piercing element; The second puncture element has a central opening at its proximal end; The second syringe has a second dispensing tip protruding from the distal end thereof, the second dispensing tip being inserted into the central opening at the proximal end of the second piercing element.
9. The sealant delivery system of claim 4, wherein the syringe assembly further comprises: a double barrel plunger comprising a first plunger rod inserted into the proximal end of the first syringe and a second plunger rod inserted into the proximal end of the second syringe; a thumb tab interconnecting a proximal end of the first plunger rod and a proximal end of the second plunger rod; The double barrel plunger is movable toward a distal end of the syringe assembly for forcing the first liquid into the first vial and forcing the second liquid into the second vial.
10. A vial assembly, comprising: a vial assembly housing having a proximal end and a distal end, the vial assembly housing having first and second side-by-side guide channels extending between the proximal and distal ends of the vial assembly housing; a first vial secured to the vial assembly housing, the first vial having a proximal end aligned with the first guide channel and a first vial opening closed at the proximal end thereof by a first sealing membrane; a first puncture element, which is disposed in the first guide channel and is movable between a retracted position and an extended position, in which the first puncture element is located proximal to the first sealing membrane, and in which the first puncture element passes through the first sealing element to puncture the first sealing membrane; a second vial secured to the vial assembly housing, the second vial having a proximal end aligned with the second guide channel and a second vial opening closed at the proximal end thereof by a second sealing membrane; and A second puncture element is arranged in the second guide channel and can be moved between a retracted position and an extended position. In the retracted position, the second puncture element is located proximal to the second sealing membrane. In the extended position, the second puncture element passes through the second sealing element to puncture the second sealing membrane.
11. The vial assembly according to claim 10, further comprising: The first puncture element has a proximal end and a distal end; a central opening, the central opening is located at the proximal end of the first puncture element, the central opening defines a first fluid passage extending along the length of the first puncture element; and a first piercing spike protruding from the distal end of the first piercing element; and The second puncture element has a proximal end and a distal end; a central opening, the central opening is located at the proximal end of the second puncture element, the central opening defines a second fluid passage extending along the length of the second puncture element; and a second piercing spike protruding from the distal end of the second piercing element.
12. The vial assembly of claim 11, wherein the first fluid pathway and the second fluid pathway are isolated from each other.
13. The vial assembly of claim 10, wherein the vial housing further comprises: a first proximal projection extending into the first guide channel, the first proximal projection being adapted to contact the first puncture element to retain the first puncture element in the retracted position; a first distal protrusion extending into the first guide channel, the first distal protrusion being adapted to contact the first puncture element to maintain the first puncture element in the extended position; a second proximal projection extending into the second guide channel, the second proximal projection being adapted to contact the second puncture element to retain the second puncture element in the retracted position; A second distal protrusion extends into the second guide channel, the second distal protrusion being adapted to contact the second puncture element to maintain the second puncture element in the extended position.
14. The sealant delivery system of claim 13, further comprising: the first piercing element comprising a first resilient flange adapted to sequentially engage the first proximal projection and the first distal projection of the vial assembly housing when the first piercing element is moved from the retracted position to the extended position within the first guide channel; The second piercing element includes a second resilient flange adapted to sequentially engage the second proximal projection and the second distal projection of the vial assembly housing when the second piercing element is moved from the retracted position to the extended position within the second guide channel.
15. A sealant delivery system, comprising the vial assembly according to claim 11, the sealant delivery system comprising: a syringe assembly including a first syringe and a second syringe side-by-side, the first syringe having a first fluid chamber and the second syringe having a second fluid chamber; The distal end of the syringe assembly is connected to the proximal end of the vial assembly housing so that the distal end of the first syringe is aligned with the central opening at the proximal end of the first puncture element, and the distal end of the second syringe is aligned with the central opening at the proximal end of the second puncture element.
16. The sealant delivery system of claim 15, further comprising: the first syringe having a first dispensing tip protruding from a distal end thereof, the first dispensing tip being in fluid communication with the first fluid compartment of the first syringe, wherein the first dispensing tip is inserted into the central opening at the proximal end of the first piercing element for providing fluid communication between the first fluid chamber and the first fluid passage extending along the length of the first piercing element; The second syringe has a second dispensing tip protruding from its distal end, and the second dispensing tip is fluidically connected to the second fluid compartment of the second syringe, wherein the second dispensing tip is inserted into the central opening at the proximal end of the second piercing element to provide fluid communication between the second fluid chamber and the second fluid passage extending along the length of the second piercing element.
17. The sealant delivery system of claim 16, further comprising: a first liquid disposed in the first fluid chamber of the first syringe and a first powdered reactive component disposed in the first vial of the vial assembly, wherein the first fluid passage provides fluid communication between the first fluid chamber and the first vial when the first piercing element is moved to the extended position; a second liquid disposed in the second fluid chamber of the second syringe and a second powdered reactive component disposed in the second vial of the vial assembly, wherein the second fluid passage provides fluid communication between the second fluid chamber and the second vial when the second piercing element is moved to the extended position.
18. A sealant delivery system, comprising: a syringe assembly including a first syringe and a second syringe side-by-side, the first syringe having a first fluid chamber containing a first fluid and the second syringe having a second fluid chamber containing a second fluid; a vial assembly coupled to a distal end of the syringe assembly, the vial assembly comprising a first vial and a second vial arranged side by side; the first vial containing a first powdered reactive component, the first vial having a proximal end aligned with the distal end of the first syringe and a first vial opening closed at the proximal end thereof by a first sealing membrane; the second vial containing a second powdered component, the second vial having a proximal end aligned with the distal end of the second syringe and a second vial opening closed at the proximal end thereof by a second sealing membrane; The vial assembly includes a first piercing element located between the distal end of the first syringe and the first sealing membrane, the first piercing element being movable between a retracted position, in which the first piercing element is located on the proximal side of the first sealing membrane, and an extended position, in which the first piercing element pierces the first sealing membrane to provide fluid communication between the first fluid chamber and the first vial; and The vial assembly includes a second piercing element located between the distal end of the second syringe and the second sealing membrane, the second piercing element being movable between a retracted position and an extended position, wherein the second piercing element is located on the proximal side of the second sealing membrane, and wherein the second piercing element pierces the second sealing membrane to provide fluid communication between the second fluid chamber and the second vial.
19. The sealant delivery system of claim 18, wherein the syringe assembly further comprises: a double barrel plunger comprising a first plunger rod inserted into the proximal end of the first syringe and a second plunger rod inserted into the proximal end of the second syringe; a tab interconnecting a proximal end of the first plunger rod and a proximal end of the second plunger rod; The double-barrel plunger is movable toward a distal end of the syringe assembly for forcing the first liquid into the first vial for reconstitution of the first powdered reactive component to produce a first therapeutic solution and forcing the second liquid into the second vial for reconstitution of the second powdered reactive component to produce a second therapeutic solution.
20. The sealant delivery system of claim 18, wherein the vial housing further comprises: a first guide channel and a second guide channel side-by-side extending between a proximal end and a distal end of the vial assembly housing; a first proximal projection extending into the first guide channel, the first proximal projection being adapted to contact the first puncture element to retain the first puncture element in the retracted position; a first distal protrusion extending into the first guide channel, the first distal protrusion being adapted to contact the first puncture element to maintain the first puncture element in the extended position; a second proximal projection extending into the second guide channel, the second proximal projection being adapted to contact the second puncture element to retain the second puncture element in the retracted position; A second distal protrusion extends into the second guide channel, the second distal protrusion being adapted to contact the second puncture element to maintain the second puncture element in the extended position.
